Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of advanced or metastatic breast cancer called HR+/HER2- (meaning the cancer is driven by hormones, but not by a protein called HER2), at a stage where surgery is not possible or where the cancer has spread to other parts of the body.
- People whose first-line cancer treatment (the first treatment given for this advanced cancer) was started between January 1, 2024 and January 1, 2027, with records of this treatment existing in a national database called NATDSS.
- People who were 18 years of age or older at the time their first-line treatment began.
- People who have at least 3 months of medical follow-up records after their first treatment began, shown by at least one clinic or hospital visit recorded in the NATDSS database during that period.
Who may not be able to join:
- People who have a diagnosis record of another serious (invasive) cancer — not including non-cancerous or early-stage tumours — within the 5 years before their breast cancer diagnosis.
- People who were diagnosed with another active invasive cancer at a different location in the body on the same day as, or within 3 months after, their breast cancer diagnosis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Distribution of first-line treatment regimens; Proportion of patients with treatment changes; Time to treatment initiation, time to discontinuation, and time to next line therapy; Proportion of patients by initial CDK4 6 inhibitor dose; Proportion of patients with dose modifications of CDK4/6 inhibitor therapy; Time to first dose modification of CDK4/6 inhibitor therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.